Project Grant R01AI192892

Award Date 6/6/25
Completion Date 5/31/30
Dollars Obligated $773K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This Project Grant award of $2,366,783.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research to determine the molecular processes by which infectious spores of the fungus Cryptococcus transition into vegetatively growing yeast (germinate) and how this process influences disease. The overarching goal is to gain a better understanding of the fundamental biology of pathogenic fungi,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $515,875 to the University of Florida to conduct research on the mechanisms underlying Cryptococcus neoformans-induced meningoencephalitis and neurotoxicity in a CD4 T cell-deficient mouse model. The goal is to elucidate how the Cryptococcus polysaccharide capsule component glucuronoxylomannan (GXM) affects basal...
This $616,588 Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to illuminate environmental sensing mechanisms in the fungal pathogen Cryptococcus neoformans, which causes deadly fungal meningitis. The award recipient, The Regents of the University of California, San Francisco (UCSF), will utilize a high-precision phenotypic profiling method to map genetic...
This $443,944.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research by the University of Georgia Research Foundation to study the genetic basis of two key pathogenesis traits in the fungal genus Cryptococcus - thermotolerance and azole drug resistance. The research aims to employ high-throughput genetic approaches to characterize how genome-wide factors...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,797,623 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to decipher the significance of pathogen genetic variation and evolution. The 5-year research project, which commenced on July 8, 2024, will use a combination of genetics and experimental evolution to understand complex epistasis with respect to genetic...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $749,594 to study the role of the host sphingosine kinase 1 (SK1) pathway in controlling Cryptococcus neoformans infection during immunodeficiency. The awardee, The Research Foundation For The State University Of New York (Stony Brook University), will use a mouse model to investigate how the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research at Prokaryotics Incorporated to develop novel antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) biosynthesis pathway. The $170,000 award, running from February 1, 2025 to January 31, 2027, supports structural elucidation of the C. albicans GPI ethanolamine phosphate transferase enzyme...
This federal Project Grant award for $158,433, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the metabolic mechanisms that allow the pathogenic fungus Cryptococcus neoformans to tolerate high levels of carbon dioxide as a virulence trait. The research will define the metabolic profile induced by carbon dioxide stress across diverse Cryptococcus isolates, and examine how...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the discovery and development of new antifungal therapeutics. The goal is to identify inhibitors of the fungal enzyme ceramide synthase 1 (CER1), which is essential for fungal growth across different environmental conditions. By targeting CER1, the project aims to develop a more potent antifungal...
This federal Project Grant award, totaling $494,696.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at the University of Texas Health Science Center at San Antonio (UTHSCSA) to investigate translational control mechanisms that enable the fungal pathogen Candida albicans to respond to host environmental stresses and transition between yeast and filamentous...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $773,053 Project Grant to The Washington University in St. Louis to conduct research on the synthesis and role of beta-1,6-glucan in the cell wall of the fungal pathogen Cryptococcus neoformans. The goal of this 5-year project is to define the biosynthesis of beta-1,6-glucan, a key component of the Cryptococcus cell wall, in order to better understand this critical process and potentially identify new antifungal therapy targets. The researchers will use biochemical, biophysical, and genetic approaches to determine how the GGT2 protein affects Cryptococcus cell wall structure and function, establish the biochemical activity of GGT2, and identify other proteins involved in beta-1,6-glucan synthesis. This research aims to increase fundamental knowledge of the Cryptococcus cell wall and processes crucial for its integrity, potentially leading to new therapeutic strategies against this global fungal pathogen.

Generated 6/24/25, 6:01 AM